Acurx Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Acurx Pharmaceuticals, Inc. (ACXP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $200.54 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $200.54K, a 38.15% decline year-over-year.
- Acurx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $258.29K, a 22.58% decline year-over-year.
- Acurx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $294.79K, a 14.60% decline year-over-year.
- Acurx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $324.22K, a 68.12% decline year-over-year.
- Acurx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.25M, a 52.06% decline from fiscal 2024.
- Acurx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.60M, a 18.86% decline from fiscal 2023.
- Acurx Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.21M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.54K 10-Q · filed 2026-08-13 | $458.82K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $258.29K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $1.25M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $294.79K 10-Q · filed 2025-11-12 | $619.01K derived: sum of 2 quarters · filed 2026-08-13 | $952.61K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $324.22K 10-Q · filed 2026-08-13 | $657.81K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $333.60K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $2.60M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $345.19K 10-Q · filed 2025-11-12 | $1.36M derived: sum of 2 quarters · filed 2025-11-12 | $2.26M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.02M 10-Q · filed 2025-11-12 | $1.91M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $894.52K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $3.21M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $833.28K 10-Q · filed 2024-11-12 | $1.64M derived: sum of 2 quarters · filed 2024-11-12 | $2.37M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $806.49K 10-Q · filed 2024-11-12 | $1.54M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $733.47K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |